Osteoarthritis is one of the leading causes of disability in the elderly. The changes in the lubricating properties of synovial fl uid lead to signifi cant pain and loss of function. More than ten years have passed from the fi rst studies. Up till now many authors have supported intra-articular hyaluronan (HA) therapy as not only a symptom-modifying therapy but also a treatment which may signifi cantly decrease the rate of deterioration of joint structure. In this review we report data relative to knee and hip treatment. The ongoing studies continue to further our understanding of the fundamental mechanisms that likely underlie the therapeutic benefi ts of this treatment but, despite recent progress, many unresolved issues require further study. Large scale double blind controlled studies must be carried out to confi rm these promising data and produce meaningful guidelines.
Introduction
Osteoarthritis is one of the leading causes of disability in the elderly. The changes in the lubricating properties of synovial fl uid lead to signifi cant pain and loss of function. Viscosupplementation, the injection of hyaluronic acid (HA) into the joints, improves the biochemical properties of synovial fl uid into osteoarthritis joints. The clinical effect is pain relief and disease modifying activity (Balazs and Denlinger 1993; Pelletier and Martel-Pelletier 1993) .
Although there are many nonsurgical therapies available for the treatment of pain associated with osteoarthritis (OA), their long-term use and safety have not been systematically followed. Intra-articular (IA) hyaluronan therapy has been used in the treatment of symptoms associated with OA of the knee with a very favorable safety profi le (Pagnano and Westrich 2005) . In this connection, the physiological and pharmacological characteristics of HA have recently been reviewed. The high concentration of HA in spinal fl uid (SF) is essential for normal joint function. The altered properties of the synovial fl uid in OA, the decrease in molecular size and concentration of HA leads to reduced rheologic properties, which affect the lubrication and protection mechanism of action of IA hyaluronan and is probably more complex than previously thought (Maneiro et al 2004) .
The hypothesis that HA could bind to specifi c receptors is now widely accepted. The cluster determinant 44 (CD44), the intracellular adhesion molecule-1 (ICAM-1) and the receptor for hyaluronate-mediated motility (RHAMM) expressed in many cells, are some of those implicated in the process (Hodge-Dufour et al 1997; Siegelman et al 1999) . The binding of HA with its specifi c receptors has been reported to trigger various intracellular signal events such as cytokine release and stimulation of cell cycle proteins. The consequences of these interactions is to stimulate cell functional activities such as cell migration and proliferation (Cao et al 2004) .
More than ten years have passed since the original explanation by Balazs and Denlinger (1993) that the favorable effects of IA HA therapy in OA was related only to the restoration of SF rheological properties (Goldberg and Buckwalter 2005) . Many subsequent studies have supported that IA HA therapy is a symptom-modifying approach that has been found to be safe and effective for reducing pain due to OA of the knee and furthermore may also signifi cantly decrease the rate of deterioration of joint structure. This statement stems from different evidences. First of all, the complex biochemical effects of HAs in the synovium and extracellular matrix of the articular cartilage, including interactions between exogenously administered HA and articular cartilage, subchondral bone, matrix proteoglycans, and collagens. In the second place, the effects of HA administration in animal models of OA, including total or partial meniscectomy and anterior cruciate ligament transectomy. Thirdly, the results of clinical trials using one HA, Hyalgan (sodium hyaluronate, molecular weight 500-730 kDa) that evaluated structural outcomes, such as joint-space width, chondrocyte density and vitality, and arthroscopic evaluation of chondropathy. Localized severe acute infl ammatory reactions reported with repeated treatment in some patients are not a class effect but may be linked to physicochemical characteristics of hylanbased treatment (Arrich et al 2005; Pagnano and Westrich 2005; Goldberg and Buckwalter 2005) .
Studies on the effects of HAs of different molecular weight (MW) on specifi c receptors have shown that the results can vary depending on the size of the HA molecules used. For example low MH HA fragments generated during joint infl ammation may promote chemokine gene expression by macrophages. Ohkawara and colleagues (2000) noticed that HA preparation of MW 0.2 × 106 Da was more effective in maintaining the survaival of blood eosinophils than HA with an MW of 3 × 106 −6 × 106 Da, proposing that the effect derived from the increased expression of granulocyte macrophage colony-stimulating factor after CD44 activation (Ohkawara et al 2000) .
Different HA products
Presently, there are several different HA products available for injection. However, the source of hyaluronic acid varies. Some products are extracted from rooster combs but a contraindication to treatment would be an allergy to eggs or chicken.
Hyaluronic acid is available in a variety of products with different molecular weight ranging from 500 KD to more than 90 millions D (Table 1 ). Hylans are cross-linked hyaluronic acids, which gives them a higher molecular weight and increased elastoviscous properties.
HA products in the intra-articular treatment of knee OA
The fi rst studies on the use of HA in human knee OA were carried out in the 1970s by Rydell and Balasz (1971) and Peyron and Balasz (1974) . In 1974, Peyron injected 1, 2, or 3 ml of HA (Healon) in 23 knees and obtained positive responses in pain and function in 74% of patients. The treatment with two injections of 2 ml HA each appeared to have the best outcome.
Recent papers have reviewed clinical trials published in the last years using different HA preparation and the results of these trials are summarized in Table 2 .
Data support the benefi t and safety of repeated treatment with IA HA. Many trials indicate that sodium hyaluronate (molecular weight [MW] 500-730 kDa) is well tolerated and as effective after multiple courses of treatment as it is after a single course (Pagnano and Westrich 2005) . Other data state that viscosupplementation is an effective treatment for patients with knee OA who have ongoing pain or are unable to tolerate conservative treatment or joint replacement.
Viscosupplementation appears to have a slower onset of action than intra-articular steroids, but the effect seems to last longer (Wang et al 2004) .
HA not only relieves the symptoms of OA but also modifi es the structure of the diseased joint and the rate of OA disease progression, at least early in the evolution of the disease process (Ohkawara et al 2000) . Based on the aforementioned analyses, viscosupplementation is an effective treatment for OA of the knee with benefi cial effects on pain, function and patient global assessment at different post injection periods but especially at the 5 to 13 week post injection period with a dramatic effect on the reduction of NSAIDs monthly consumption.
However, there are few randomized head-to-head comparisons of different viscosupplements and readers should be cautious, therefore, in drawing conclusions regarding the relative value of different products.
In some analyses, viscosupplements were comparable in effi cacy to systemic forms of treatment, with more local reactions but fewer systemic adverse events. In other analyses HA products had more prolonged effects than IA corticosteroids. Overall, the aforementioned analyses support the use of the HA class of products in the treatment of knee OA (Lo et al 2003) . In one systematic review, IA HA has not been proven clinically effective and may be associated with minimal and transient risk of adverse events (Arrich et al 2005) .
At present no case of septic arthritis has been reported in any clinical trial. Most adverse events are minor and transient at the injection site. Painful post-injection reaction occurred in 1%-2% of patients, the pain did not last more than 72 hours. Systemic allergic reactions due to individual hypersensitivity were rarely recorded. Therefore viscosupplementation seems to be an effi cacious and safe treatment.
The heterogeneity of these studies limits definitive conclusions on different treatment regimen with diverse molecular weight HA but in our opinion we think that the different HA products act with the same class effect (Axe and Shields 2005) . Furthermore preliminary data indicate a potential use for hyaluronans in the treatment of infl ammatory arthropathies (eg, acute joint trauma and fractures) that require long periods of immobilization, and in tissue engineering for chondral defects. Although the trials that have investigated the use of hyaluronan therapy for the management of traumatic and degenerative musculoskeletal disorders seen in sports medicine have limitations in design and patient number, the results have been promising and suggest that larger controlled clinical trials are warranted (Peyron and Balasz 1974) .
HA products in the intra-articular treatment of hip OA
Few data exists in literature about the viscosupplementation of hip OA in spite of it is the second most common site of the disease after the knee (Pelletier and Martel-Pelletier 1993; Pagnano and Westrich 2005) . One of the limiting factors for this practice might be related to the injection procedure. The intra-articular injection of the hip is not as easy as for the knee, mainly for anatomical features of the joint and the proximity of "sensitive" structures such as the femoral artery and nerves. Even though hip injection may be performed "blindly", failure rate is nevertheless signifi cant (Jones et al 1993) and when using a slow absorbing viscosupplement like hyaluronan, the potential local complications may jeopardize the therapeutic benefi t (Jackson et al 2002) . For such reasons, it has been suggested to perform intra-articular injection of the hip under radiological or ultrasound control. Although several ultrasound guidance techniques were available (Qvistgaard et al 2001) , we developed a personal one using an antero-superior approach (Migliore et al 2003) .
Since no single or double blind randomized controlled trials have yet been published, we analyzed all the available trials on MEDLINE to assess viscosupplementation for the treatment of hip OA (Table 3 ).
The effi cacy data underlines signifi cant improvement in pain and function as has been shown in the knee OA studies despite the small size of the sample. The short period of observation has not seen a change in the natural history of the disease. In order to confi rm these promising data, large scale double blind controlled studies must be carried out.
Conclusions
The ongoing studies continue to further our understanding of the fundamental mechanisms that likely underlie the therapeutic benefi ts of this treatment. The meta-analysis in progress are further establishing a role for viscosupplementation in ameliorating the symptoms of knee and hip osteoarthritis. At the moment it is clear that viscosupplementation is more effi cacious in the initial and intermediate stages of OA more than at an advanced stages and that this therapy is exceptionally safe compared with other OA treatments.
Despite recent progress, many unresolved issues require further study. These include determining the costeffectiveness of viscosupplementation, exploring the therapeutic effectiveness and safety, clearly defi ning the relation between molecular weight and the clinical effectiveness of the various hyaluronan products, establishing optimal dosing regiments, evaluating effi cacy in different OA populations, determining how to best incorporate viscosupplementation into the evolving OA treatments algorithms, exploring the potential for treatment of OA joints other than the knee, as already shown for the hip, and assessing potential synergistic or additive effects with other modalities such NSAIDs and SYSADOA.
It is encouraging that hyaluronan-based therapy is proving to be safe and effective for many patients with symptomatic hip and knee OA despite the fact that many unresolved issues requiring further study remain. If hyaluronan derivatives are eventually proven to have clear Intra-articular use of hyaluronic acid in osteoarthritis disease-modifying effects, it may then be reasonable to consider their use early in cartilage injury or disease, before the onset of syntomatic OA. Additional well-designed randomized controlled trials with high methodological quality are needed to resolve the continued uncertainty about the therapeutic effects of different types of hyaluronic acid products on osteoarthritis in various clinical situations and patient populations (Wang et al 2004) .
At the moment the Arthritis Foundation believes that while more studies are needed to determine the long-term results of such treatments, HA provides an option for people with knee OA who have not responded well to drug treatments or exercise and physical therapy. It also may be appropriate for those who may be at increased risk for upper gastrointestinal (GI) complications, such as patients who: are over 65 years old; are taking oral corticosteroids and/or anticoagulants; have a history of peptic ulcer disease or upper GI bleeding; are smokers; and consume high volumes of alcohol. HA also may be considered in patients with kidney failure.
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